Medexus Current Deferred Revenue from 2010 to 2026
| MDP Stock | 2.74 0.07 2.49% |
Current Deferred Revenue | First Reported 2012-12-31 | Previous Quarter 40 M | Current Value 4.5 M | Quarterly Volatility 9.1 M |
Check Medexus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medexus Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 34.2 M, Other Operating Expenses of 120.9 M or Operating Income of 9.9 M, as well as many indicators such as Price To Sales Ratio of 0.63, Dividend Yield of 0.0 or PTB Ratio of 1.31. Medexus financial statements analysis is a perfect complement when working with Medexus Pharmaceuticals Valuation or Volatility modules.
Medexus | Current Deferred Revenue |
Evaluating Medexus Pharmaceuticals's Current Deferred Revenue across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Medexus Pharmaceuticals's fundamental strength.
Latest Medexus Pharmaceuticals' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Medexus Pharmaceuticals over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Medexus Pharmaceuticals' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Medexus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Medexus Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 14,129,124 | |
| Geometric Mean | 19,715 | |
| Coefficient Of Variation | 133.87 | |
| Mean Deviation | 16,498,109 | |
| Median | 264,327 | |
| Standard Deviation | 18,914,227 | |
| Sample Variance | 357.7T | |
| Range | 48.3M | |
| R-Value | 0.88 | |
| Mean Square Error | 85.5T | |
| R-Squared | 0.78 | |
| Slope | 3,299,284 | |
| Total Sum of Squares | 5724T |
Medexus Current Deferred Revenue History
About Medexus Pharmaceuticals Financial Statements
Medexus Pharmaceuticals investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Medexus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 46 M | 48.3 M |
Pair Trading with Medexus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Medexus Stock
Moving against Medexus Stock
The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.
The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medexus Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.